TGFB1 and renal cell carcinoma: Collectively, our data suggest that HL-RG may treat RCC by modulating TGFB1/CCND1/MMP9/ERBB2/CAT/PPARα networks via NF-κB, PI3K/AKT, and TGF-β pathways.